Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Pamidronsäure, ATC M05BA03 für die Zeit 01.01.2027 - 31.12.2028 (zzgl. V.-Option 1x12 Monate)
Description
Section 130a Paragraph 8 of the SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the awarding of public contracts, the DAK-Gesundheit regularly carries out substance-related formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For the medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned substance Pamidronic acid, ATC M05BA03, the DAK-Gesundheit intends to conclude medicine discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine discount contracts. A discount contract under the licensing model for the aforementioned substance will come into force for the first time on 01.01.2027 and will end on 31.12.2028 (plus extension option 1x12 months). It will automatically end with the entry into force of the exclusive contract, regardless.
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Mometason (ausschl. in der Dafo. Lösung), ATC D07AC13 f. d. Z. 01.01.2027-31.12.2028 (zzgl. V.-Option 1x12 M)
DAK-GesundheitGermanyPharmaceutical productsDeadline in 1,084 daysPublished on Nov 16, 2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Morphin (ausschl. in der Dafo. FTA + HKP + SMT), ATC N02AA01 f. d. Z. 01.01.27-31.12.28, zzgl V.-Option 1x12M
DAK-GesundheitGermanyPharmaceutical productsDeadline in 1,084 daysPublished on Nov 16, 2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Glycopyrronium + Indacaterol, ATC R03AL12 für die Zeit 01.01.2027 - 31.12.2028
DAK-GesundheitGermanyPharmaceutical productsDeadline in 719 daysPublished on Nov 16, 2026
Germany – Incubators – Inkubatoren und Wärmebetten Klinikum Oldenburg
Klinikum Oldenburg AöRGermanyIncubatorsDeadline in 31 daysPublished on Nov 16, 2026